Capricor Therapeutics (NASDAQ:CAPR) Trading Down 2.9% – What’s Next?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares traded down 2.9% on Tuesday . The stock traded as low as $13.61 and last traded at $13.72. 58,980 shares were traded during trading, a decline of 95% from the average session volume of 1,196,164 shares. The stock had previously closed at $14.13.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Cantor Fitzgerald raised their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, November 14th. Piper Sandler initiated coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Finally, Maxim Group boosted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Trading Down 2.5 %

The stock has a fifty day simple moving average of $17.83 and a 200-day simple moving average of $10.40. The company has a market capitalization of $626.12 million, a PE ratio of -12.99 and a beta of 3.98.

Institutional Trading of Capricor Therapeutics

A number of large investors have recently bought and sold shares of CAPR. Virtu Financial LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter valued at about $458,000. Barclays PLC lifted its position in Capricor Therapeutics by 106.6% in the third quarter. Barclays PLC now owns 36,296 shares of the biotechnology company’s stock valued at $552,000 after purchasing an additional 18,724 shares during the period. Sphera Funds Management LTD. purchased a new stake in Capricor Therapeutics in the 3rd quarter valued at approximately $938,000. State Street Corp increased its position in Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after purchasing an additional 111,291 shares during the period. Finally, Sassicaia Capital Advisers LLC purchased a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $192,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.